168 related articles for article (PubMed ID: 19275550)
1. Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.
Yamagishi S; Matsui T; Ueda S; Fukami K; Okuda S
Curr Drug Metab; 2009 Feb; 10(2):159-63. PubMed ID: 19275550
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
3. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
4. Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.
Nakamura K; Yamagishi S; Matsui T; Inoue H
Drugs Exp Clin Res; 2005; 31(4):155-9. PubMed ID: 16223205
[TBL] [Abstract][Full Text] [Related]
5. Postprandial hyperglycaemia and vascular damage--the benefits of acarbose.
Båvenholm PN; Efendic S
Diab Vasc Dis Res; 2006 Sep; 3(2):72-9. PubMed ID: 17058626
[TBL] [Abstract][Full Text] [Related]
6. Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation.
Standl E; Schnell O
Diab Vasc Dis Res; 2012 Jul; 9(3):163-9. PubMed ID: 22508699
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Yamada K
Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of black tea and its combination with acarbose on small intestinal α-glucosidase activity.
Satoh T; Igarashi M; Yamada S; Takahashi N; Watanabe K
J Ethnopharmacol; 2015 Feb; 161():147-55. PubMed ID: 25523370
[TBL] [Abstract][Full Text] [Related]
9. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
[TBL] [Abstract][Full Text] [Related]
10. [alpha-Glucosidase inhibitor, its structure and mechanism of antidiabetic action].
Odaka H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():393-8. PubMed ID: 12387024
[No Abstract] [Full Text] [Related]
11. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.
Joshi SR; Standl E; Tong N; Shah P; Kalra S; Rathod R
Expert Opin Pharmacother; 2015; 16(13):1959-81. PubMed ID: 26255950
[TBL] [Abstract][Full Text] [Related]
12. Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms.
Fujisawa T; Ikegami H; Inoue K; Kawabata Y; Ogihara T
Metabolism; 2005 Mar; 54(3):387-90. PubMed ID: 15736118
[TBL] [Abstract][Full Text] [Related]
13. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
[TBL] [Abstract][Full Text] [Related]
14. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
[TBL] [Abstract][Full Text] [Related]
15. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; De Grauw WJ
Cochrane Database Syst Rev; 2006 Oct; (4):CD005061. PubMed ID: 17054235
[TBL] [Abstract][Full Text] [Related]
16. Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?
Charpentier G; Riveline JP; Dardari D; Varroud-Vial M
Drugs; 2006; 66(3):273-86. PubMed ID: 16526817
[TBL] [Abstract][Full Text] [Related]
17. Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system.
Rosak C; Mertes G
Curr Diabetes Rev; 2009 Aug; 5(3):157-64. PubMed ID: 19689250
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
Yamazaki K; Inoue T; Yasuda N; Sato Y; Nagakura T; Takenaka O; Clark R; Saeki T; Tanaka I
J Pharmacol Sci; 2007 May; 104(1):29-38. PubMed ID: 17485917
[TBL] [Abstract][Full Text] [Related]
20. Who should benefit from the use of alpha-glucosidase inhibitors?
Godbout A; Chiasson JL
Curr Diab Rep; 2007 Oct; 7(5):333-9. PubMed ID: 18173965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
